Association between alopecia and response to chemotherapy in patients with Hodgkin lymphoma

Therapeutic Drug Monitoring

Volumn 27, Issue 3, 2005, Pages 287-289

  Elis, Avishay ^a   Blickstein, Dorit ^b,c   Manor, Yosef ^a   Lishner, Michael ^a  

^a MEIR MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alopecia; Bone marrow suppression; Hodgkin lymphoma; Response to doxorubicin

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

ADULT; ALOPECIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; HAIR LOSS; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ALOPECIA; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED;

EID: 20044364756     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000158867.66994.91     Document Type: Review

References (17)

1. Levantine A, Almeyda J. Drug induced alopecia. Br J Dermatol. 1973;89:549-553.
2. Dean JC, Salmon SE, Griffith KS. Prevention of doxorubicin-induced hair loss with scalp hypothermia. N Engl J Med. 1979;301:1427-1429.
3. Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin North Am. 1986;70:187-206.
4. Editorial. Cancer, cancer therapy and hair. Lancet. 1993;2:1177-1178.
5. Umeki S, Niki Y, Soejima R. Anticancer chemotherapy accelerates scalp hair loss with no androgenic involvement. Chemotherapy. 1989;35:54-57.
6. Barry MA, Benkhe CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol. 1990;40:2353-2362.
7. Lishner M, Manor Y, Kitay-Cohen Y, et al. Association between alopecia and response to aggressive chemotherapy in patients with Hodgkin's disease. Med Hypotheses. 1999;53:447-449.
8. Crounse RG, Van Scott EJ. Changes in scalp hair root as a measure of toxicity from cancer chemotherapeutic drugs. J Invest Dermatol. 1960;35:83-90.
9. Klimo P, Connors JM. MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease. J Clin Oncol. 1985;3:1174-1182.
10. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478-1484.
11. Eksborg S, Strandler HS, Edsmyr F, et al. Pharmacokinetic study of I.V. infusion of adriamycin. Eur J Clin Pharmacol. 1985;28:205-212.
12. Piscitelli SC, Rodvold KA, Rushing DA, et al. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther. 1993;53:555-561.
13. Andersen A, Holte H, Slordal L. Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. Cancer Chemother Pharmacol. 1999;44:422-426.
14. Cece R, Cazzaniga S, Morelli D, et al. Apoptosis of hair follicle cells during doxorubicin-induced alopecia in rats. Lab Invest. 1996;75:601-609.
15. Eastman A. Activation of programmed cell death by anti-cancer agents: cisplatin as a model system. Cancer Cells. 1990;2:275-280.
16. Demarcq C, Bunch RT, Creswell D, et al. The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells. Cell Growth Differ. 1994;5:983-993.
17. Davis ST, Benson BG, Bramson HN, et al. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science. 2001;291:134-137.